McKinsey & Company, Inc., National Prescription Opiate Consultant Litigation
McKinsey's alleged role in the opioid epidemic involved strategic consulting that promoted aggressive marketing of opioids as safe and non-addictive, influencing prescriber behavior and increasing prescriptions. This led to widespread misuse, addiction, and overdose deaths. The pathways of harm include targeted marketing to healthcare providers, setting sales targets, and minimizing perceived risks, which collectively contributed to the public health crisis.
235
Pending actions
262
Total actions filed
Active
Status
06/07/2021
Established
Who qualifies
Plaintiffs must demonstrate injury linked to opioid use or overdose, with evidence such as medical records, prescriptions, and expert testimony. Exposure during specific periods, typically post-2010, and a causal connection to McKinsey's consulting advice are required.
Products involved
- Prescription opioids
- OxyContin
Alleged injuries
- Addiction
- Overdose
- Dependency
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.